Remove 2019 Remove Leads Remove Medical science
article thumbnail

How AI Can Help Medical Science Liaisons Juggle Their Ever-Growing Responsibilities

PM360

Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. 1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. But that’s just the beginning.

article thumbnail

Recurrent drug shortages signal onerous outlook for cardiovascular care

Pharmaceutical Technology

This is due to aging populations around the world, which leads to an increased risk of such conditions, explains Craig Beavers, PhD, assistant professor at the University of Kentucky’s College of Pharmacy in Lexington. Also, substitution can lead to further shortages, he adds. Critical care especially hit.

Medicine 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe. 2019 [cited 2023 Apr 4]. 1,2 In the EU, an estimated 2.7

Patients 105
article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. 2019 [cited 2023Feb]. the enteric coating and the capsule dissolve. Pharmaceutics.

article thumbnail

Five Ways Asia Pacific Life Science Industry Leaders Are Enhancing Customer Experience

Veeva

This engagement is continuing to remain high, with evolving requirements and preferences of healthcare practitioners (HCPs) in the ways they engage with pharma reps and medical science liaisons (MSLs) through virtual communications. We have identified five steps to delivering more engaging customer experiences with HCPs and patients.

Pharma 52
article thumbnail

Targeted therapies for chronic lymphocytic leukaemia in an evolving treatment landscape

European Pharmaceutical Review

Chronic lymphocytic leukaemia (CLL) is the most prevalent adult leukaemia in Western countries with more than 100,000 incidences and more than 40,000 deaths reported globally in 2019. About the author Dr Mehrdad Mobasher, MPH, is the Chief Medical Officer for Hematology at BeiGene. References Yao Y, Lin X, Li F, Jin J, Wang H.

Safety 52